NEWARK, DE--(Marketwired - April 24, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance of a Chinese patent on its lichenase fusion protein technology for therapeutic proteins and vaccines.
"The invention covered by this patent enables increased efficiency in the expression of a range of commercially important proteins," said Dr. Wayne Fitzmaurice, iBio's vice-president of intellectual property. "The allowed claims cover both composition of matter and uses of the technology for both therapeutic products and vaccines."
Robert Erwin, iBio's president, commented: "China is another important market for our technology and products. Like Brazil, China is a fast growing healthcare market which has no substantial history or prior commitment to older biotechnologies that would compete with our iBioLaunch™ and iBioModulator™ solutions."
The company recently launched a new subsidiary, iBio Brazil, to facilitate entry of biosimilar therapeutics in Brazil. iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 in Brazil to develop a recombinant yellow fever vaccine based upon iBio technology. iBio's success in Brazil is expected to serve as a template for other iBio projects worldwide.
The allowed patent application, "Recombinant Carrier Molecule for Expression, Delivery and Purification of Target Polypeptides," is based on an invention developed by scientists at the company's research and technology collaborator, the Fraunhofer USA Center for Molecular Biotechnology. The invention is owned by iBio. When this patent issues, it will add to the company's fusion protein and iBioModulator patents in the U.S., Australia, Canada, India and Europe (Germany, France, Italy, Ireland, Spain, and Great Britain).
About iBio, Inc.
iBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.
The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com.
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.